Core Alternative Capital’s West Pharmaceutical WST Stock Holding History

Core Alternative Capital’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3	Closed	-$787	–	344
2025 Q3	$787	Hold	3	–	–	﹤0.01%	303
2025 Q2	$656	Hold	3	–	–	﹤0.01%	306
2025 Q1	$672	Hold	3	–	–	﹤0.01%	306
2024 Q4	$983	Hold	3	–	–	﹤0.01%	312
2024 Q3	$900	Hold	3	–	–	﹤0.01%	319
2024 Q2	$988	Hold	3	–	–	﹤0.01%	307
2024 Q1	$1.19K	Sell	3 -19	-86%	-$7.03K	﹤0.01%	292
2023 Q4	$7.75K	Sell	22 -1	-4%	-$354	﹤0.01%	329
2023 Q3	$8.63K	Hold	23	–	–	﹤0.01%	336
2023 Q2	$8.8K	Buy	23 +1	+5%	+$357	﹤0.01%	326
2023 Q1	$7.63K	Buy	22 +4	+22%	+$1.17K	﹤0.01%	339
2022 Q4	$4.24K	Hold	18	–	–	﹤0.01%	353
2022 Q3	$4K	Hold	18	–	–	﹤0.01%	383
2022 Q2	$5K	Buy	18 +5	+38%	+$1.63K	﹤0.01%	369
2022 Q1	$5K	Buy	13 +9	+225%	+$3.52K	﹤0.01%	366
2021 Q4	$2K	Buy	+4	New	+$1.72K	﹤0.01%	343

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Core Alternative Capital's WST Position: Q4 2025 in Review

Core Alternative Capital sold out of West Pharmaceutical (WST) in Q4 2025, closing a stake of 3 shares — an estimated $787 sold.

Core Alternative Capital first reported a position in WST in Q4 2021 and held it in 16 quarters. The position peaked at $8.8K in Q2 2023. 804 funds tracked by Wall St. Rank hold WST as of Q4 2025.

Core Alternative Capital reported no remaining West Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Core Alternative Capital sold 3 West Pharmaceutical shares in Q4 2025, an estimated $787.
Core Alternative Capital first reported a position in West Pharmaceutical in Q4 2021 and held it in 16 quarters.
Core Alternative Capital's West Pharmaceutical position peaked at $8.8K in Q2 2023.
804 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2025.

Based on Core Alternative Capital's 13F filing for Q4 2025, filed 2 Feb 2026.